Setback for AZ’ asthma drug as trial misses endpoint

AstraZeneca’s tralokinumab has failed to significantly reduce the rate of annual exacerbations in patients with uncontrolled asthma taking part in a late-stage trial.

Spotlight

Other News

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More